1887

Abstract

Increased human-to-human transmission of monkeypox virus (MPXV) is cause for concern, and antibodies directed against vaccinia virus (VACV) are known to confer cross-protection against Mpox. We used 430 serum samples derived from the Scottish patient population to investigate antibody-mediated cross-neutralization against MPXV. By combining electrochemiluminescence immunoassays with live-virus neutralization assays, we show that people born when smallpox vaccination was routinely offered in the United Kingdom have increased levels of antibodies that cross-neutralize MPXV. Our results suggest that age is a risk factor of Mpox infection, and people born after 1971 are at higher risk of infection upon exposure.

Funding
This study was supported by the:
  • Biotechnology and Biological Sciences Research Council (Award BB/X011607/1)
    • Principle Award Recipient: ApplicableNot
  • Medical Research Council (Award MC_UU_00034/2)
    • Principle Award Recipient: R MurciaPablo
  • Medical Research Council (Award MC_UU_00034/3)
    • Principle Award Recipient: R MurciaPablo
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author’s institution.
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001999
2024-06-11
2024-07-15
Loading full text...

Full text loading...

/deliver/fulltext/jgv/105/6/jgv001999.html?itemId=/content/journal/jgv/10.1099/jgv.0.001999&mimeType=html&fmt=ahah

References

  1. Karagoz A, Tombuloglu H, Alsaeed M, Tombuloglu G, AlRubaish AA et al. Monkeypox (mpox) virus: classification, origin, transmission, genome organization, antiviral drugs, and molecular diagnosis. J Infect Public Health 2023; 16:531–541 [View Article] [PubMed]
    [Google Scholar]
  2. Essbauer S, Pfeffer M, Meyer H. Zoonotic poxviruses. Vet Microbiol 2010; 140:229–236 [View Article] [PubMed]
    [Google Scholar]
  3. WHO Multi-country outbreak of mpox, External situation report#27 – 14 August 2023; 2023 https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox--external-situation-report-27---14-august-2023 accessed 5 September 2023
  4. Millward G. Vaccinating Britain: Mass Vaccination and the Public since the Second World War (Wellcome Trust-Funded Monographs and Book Chapters Manchester (UK): 2019 [View Article]
    [Google Scholar]
  5. Arita I, Breman JG. Evaluation of smallpox vaccination policy. Bull World Health Organ 1979; 57:1–9 [PubMed]
    [Google Scholar]
  6. Chan CEZ, Wong SKK, Yazid NBM, Ng OT, Marimuthu K et al. Residual humoral immunity sustained over decades in a cohort of vaccinia-vaccinated individuals. J Infect Dis 2023; 227:1002–1006 [View Article] [PubMed]
    [Google Scholar]
  7. Pütz MM, Alberini I, Midgley CM, Manini I, Montomoli E et al. Prevalence of antibodies to vaccinia virus after smallpox vaccination in Italy. J Gen Virol 2005; 86:2955–2960 [View Article] [PubMed]
    [Google Scholar]
  8. Stittelaar KJ, van Amerongen G, Kondova I, Kuiken T, van Lavieren RF et al. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J Virol 2005; 79:7845–7851 [View Article] [PubMed]
    [Google Scholar]
  9. Wolff Sagy Y, Zucker R, Hammerman A, Markovits H, Arieh NG et al. Real-world effectiveness of a single dose of mpox vaccine in males. Nat Med 2023; 29:748–752 [View Article] [PubMed]
    [Google Scholar]
  10. Gilchuk I, Gilchuk P, Sapparapu G, Lampley R, Singh V et al. Cross-neutralizing and protective human antibody specificities to poxvirus infections. Cell 2016; 167:684–694 [View Article] [PubMed]
    [Google Scholar]
  11. Hammarlund E, Lewis MW, Hansen SG, Strelow LI, Nelson JA et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003; 9:1131–1137 [View Article] [PubMed]
    [Google Scholar]
  12. Criscuolo E, Giuliani B, Ferrarese R, Ferrari D, Locatelli M et al. Smallpox vaccination-elicited antibodies cross-neutralize 2022-Monkeypox virus Clade II. J Med Virol 2023; 95:e28643 [View Article] [PubMed]
    [Google Scholar]
  13. Berry MT, Khan SR, Schlub TE, Notaras A, Kunasekaran M et al. Predicting vaccine effectiveness for mpox. Nat Commun 2024; 15:3856 [View Article] [PubMed]
    [Google Scholar]
  14. Zaeck LM, Lamers MM, Verstrepen BE, Bestebroer TM, van Royen ME et al. Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals. Nat Med 2023; 29:270–278 [View Article] [PubMed]
    [Google Scholar]
  15. Adamo S, Gao Y, Sekine T, Mily A, Wu J et al. Memory profiles distinguish cross-reactive and virus-specific T cell immunity to mpox. Cell Host Microbe 2023; 31:928–936 [View Article] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.001999
Loading
/content/journal/jgv/10.1099/jgv.0.001999
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Supplementary material 2

EXCEL
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error